Art. -Nr.: HY-B0636

Triamcinolone acetonide

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 76-25-5
Formel: C₂₄H₃₁FO₆
Molecular Weight:434.50

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Triamcinolone acetonide Chemical Structure

CAS. Nr.: 76-25-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
NIH3T3	IC₅₀	2.5 μM Compound: 2 ; Triamcinolone acetonide (TA)	Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay	[PMID: 11855992]

In Vitro

Triamcinolone acetonide (0.05-3 mg/mL, 48-60 h) decreases the proliferation of BRECs with increasing concentration^[1].
Triamcinolone acetonide (0.04-5 mg/mL, 24 h) reduces chondrocyte viability in both normal and osteoarthritic (OA) chondrocytes in a concentration-dependent manner^[2].
Triamcinolone acetonide (0.04-5 mg/mL, 24 h) increases the severity of cartilage structural damage, chondrocyte loss and cluster formation, and proteoglycan loss in OA cartilage^[2].
Triamcinolone acetonide (100 nM, 7 days) strongly induces monocyte differentiation towards an M2 and anti-inflammatory macrophage phenotype^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Chondrocyte
Concentration:

0.04, 0.08, 0.16, 0.31, 0.63, 1.25, 2.5, and 5 mg/ml
Incubation Time:

24 h
Result:

Reduced cell viability with the value of IC₅₀ was 2.23 mg/mL in normal chondrocytes and 1.14 mg/mL in OA chondrocytes.

In Vivo

Triamcinolone acetonide (1.43 mg/mL, Intraperitoneal injection, once a week for 6-12 weeks) enhances folate receptor beta (FRβ)-related macrophage activation and fully prevents osteophyte development in an in vivo rat model of Osteoarthritis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Severe OA rat model ^[3]
Dosage:

1.43 mg/mL
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased body weight during OA induction.
Showed more macrophage activation and minimal or no osteophyte formation when injected knee joints.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 76-25-5
Appearance Solid
Molecular Weight 434.50
Formel C₂₄H₃₁FO₆
Color White to off-white
SMILES

OCC([C@]12[C@@]3([C@@]([C@@]4([H])[C@]([C@H](C3)O)([C@@]5(C(CC4)=CC(C=C5)=O)C)F)([H])C[C@@]1([H])OC(C)(O2)C)C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Histological Imaging/StainingIn Vivo Efficacy StudyIFIHC

Sort by:

Journal Impact Factor

Proc Natl Acad Sci U S A

NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. [Abstract]

2024 Apr 2;121(14):e2321611121. PMID: 38547058
Biochim Biophys Acta Mol Cell Res

Botulinum toxin A prevents hypertrophic scarring by suppressing PARP14/SOCS2-mediated M2 polarization of macrophages. [Abstract]

2025 Jun 10:120003. PMID: 40505894

Triamcinolone acetonide purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2025 Jun 10:120003. [Abstract]

Triamcinolone acetonide (TA) (0.05 mL/g) treatment reduced dermal thickness and epidermal hyperplasia, decreased cell numbers, increased the number of dermal appendages, and significantly decreased the scar cross-sectional area in HS mice.

Triamcinolone acetonide purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2025 Jun 10:120003. [Abstract]

Triamcinolone acetonide (TA) (0.05 mL/g) reduced collagen deposition in the scars and diminished the fibrotic area at the injury site in HS mice.

Triamcinolone acetonide purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2025 Jun 10:120003. [Abstract]

Triamcinolone acetonide (TA) (0.05 mL/g) significantly reduced the relative fluorescence intensity of α-SMA, a marker of myofibroblasts and indicative of collagen matrix contraction ability in the scar tissues of HS mice.

Triamcinolone acetonide purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2025 Jun 10:120003. [Abstract]

Triamcinolone acetonide (TA) (0.05 mL/g) significantly reduced the levels of CD31 and Ki67, marker proteins of angiogenesis and proliferation, in the scar tissue of HS mice.
Drug Test Anal

High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]

2021 Feb;13(2):283-298. PMID: 32852861
Ghent university

Triamcinolone acetonide purchased from MedChemExpress. Usage Cited in: Ghent university

Simulation output of Triamcinolone acetonide (TA) (4 mg; i.v.; 2500 h) ocular rabbit model. Observed (squares) and predicted (solid line) values in VH (green), AH (red), and plasma (blue). Concentrations in ng/mL.
SSRN

2023 Oct 31.
Patent

US20210252159A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (115.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3015 mL

11.5075 mL

23.0150 mL

5 mM

0.4603 mL

2.3015 mL

4.6030 mL

10 mM

0.2301 mL

1.1507 mL

2.3015 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Spandau U H M, et al. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo [J]. British journal of ophthalmology, 2005, 89(6): 745-747.

[2]. Euppayo T, et al. In vitro effects of triamcinolone acetonide and in combination with hyaluronan on canine normal and spontaneous osteoarthritis articular cartilage [J]. In Vitro Cellular & Developmental Biology-Animal, 2016, 52: 723-735.

[3]. Siebelt M, et al. Triamcinolone acetonide activates an anti-inflammatory and folate receptor–positive macrophage that prevents osteophytosis in vivo [J]. Arthritis research & therapy, 2015, 17(1): 1-13.

[4]. Jensen J M, et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right–left arm trial [J]. Acta Dermato-Venereologica, 2013, 93(5): 515-519.

[5]. http://en.wikipedia.org/wiki/Triamcinolone_acetonide

[6]. Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3015 mL	11.5075 mL	23.0150 mL	57.5374 mL
	5 mM	0.4603 mL	2.3015 mL	4.6030 mL	11.5075 mL
	10 mM	0.2301 mL	1.1507 mL	2.3015 mL	5.7537 mL
	15 mM	0.1534 mL	0.7672 mL	1.5343 mL	3.8358 mL
	20 mM	0.1151 mL	0.5754 mL	1.1507 mL	2.8769 mL
	25 mM	0.0921 mL	0.4603 mL	0.9206 mL	2.3015 mL
	30 mM	0.0767 mL	0.3836 mL	0.7672 mL	1.9179 mL
	40 mM	0.0575 mL	0.2877 mL	0.5754 mL	1.4384 mL
	50 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL
	60 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9590 mL
	80 mM	0.0288 mL	0.1438 mL	0.2877 mL	0.7192 mL
	100 mM	0.0230 mL	0.1151 mL	0.2301 mL	0.5754 mL

Keywords

Triamcinolone acetonide

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Triamcinolone acetonide

Immunology/Inflammation Compound Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Animal Drug Library

Steroid Hormones Library

Publications Citing Use of MedChemExpress (MCE) Triamcinolone acetonide

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Triamcinolone acetonide

Immunology/Inflammation Compound Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Animal Drug Library

Steroid Hormones Library

Publications Citing Use of MedChemExpress (MCE) Triamcinolone acetonide

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Triamcinolone acetonide Related Classifications

HY-B0636 Related Classifications